Contraceptive Technology Update
RSSArticles
-
Emphasize importance of HPV vaccine for prevention of cancer
Sixty-nine of the top cancer centers in the United States have joined to emphasize the importance of human papillomavirus vaccination for the prevention of cancer. Despite the availability of three HPV vaccines, vaccination rates lag far behind those of other routine adolescent vaccines.
-
Contraceptive selection for women with epilepsy
Epilepsy is common, affecting 2.2 million Americans, of which approximately half are women of reproductive age.1 The Association of Reproductive Health Professionals has just released a webinar, “Women with Nerve: Providing Reproductive Health Care for Women with Epilepsy,” to help providers review evidence-based information on the subject.
-
U.S. Preventive Services Task Force issues new breast cancer screening guidance
The U.S. Preventive Services Task Force has issued new guidance on breast cancer screening and called for mammography every two years for women ages 50-74. For women ages 40-49, the Task Force recommends informed, individualized decision-making based on a woman’s values, preferences, and health history.
-
Zika infections: Obtain perspective on impact of virus and how to offer effective contraception to women
Zika infections are viral infections spread from an infected person by a mosquito called the Aedes aegypti mosquito. For the Zika infection to gain a foothold in an area of the world, it must be an area that sustains Aedes aegypti mosquitoes, which is the case for all countries in our hemisphere, except for Canada, which is too cold, and Chile, which is too cold and too dry.
-
Sexual transmission of Zika virus possible: Will it impact virus spread?
News of the rapid spread of the Zika virus through 18 Latin American countries and the Caribbean has captured headlines. The World Health Organization predicts that the virus could affect more than 4 million people in the Americas in 2016 alone.
-
Azithromycin remains effective in treatment of urogenital chlamydia, study data suggest
Results of a new study, conducted by researchers at the University of Alabama at Birmingham, the Los Angeles-based University of Southern California, and the Los Angeles County Department of Health Services, confirm that azithromycin remains effective in the treatment of urogenital chlamydia.1
-
Snapshot from National HIV Prevention Conference: Strides have been made, yet hurdles remain
The December 2015 National HIV Prevention Conference saw exciting developments announced by the CDC and partners, including new data on trends and disparities in the U.S. HIV epidemic.
-
New option for vaginal discomfort after menopause
Results of a recent Phase III trial suggest that intravaginal dehydroepiandrosterone could provide women who cannot or do not wish to use intravaginal estrogen with an effective vaginal alternative for easing vaginal symptoms and pain with sex after meno-pause.1 The drug, under development as Intrarosa by Endoceutics, a North American biopharma company, is under review by the FDA.
-
Supreme Court cases loom large in 2016
The most consequential reproductive health-related drama in Congress in 2016 most likely played out in January.
-
Elevated testosterone levels might increase risk of uterine fibroids
Women who have high levels of both testosterone and estrogen in midlife might face a greater risk of developing benign uterine fibroids than women with low levels of the hormones, results of a new study indicate.1